Hypoglycemic activities of MTP-3631, a novel thiopyranopyrimidine derivative.
MTP-3631 is a novel thiopyranopyrimidine derivative structurally different from any existent hypoglycemic agents. MTP-3631 markedly decreased basal blood glucose and improved glucose intolerance in genetically diabetic C57BL/6J ob/ob mice, which was not affected by tolbutamide. MTP-3631 also caused hypoglycemic effects in normal rats, but no change was observed in plasma insulin level. Unlike buformin, MTP-3631 did not change plasma lactate level in ob/ob mice. These results suggest that the hypoglycemic mechanism of MTP-3631 may be essentially different from those of sulfonylureas and biguanides.
Ogawa
H
H
New Drug Research Laboratory, Maruko Pharmaceutical Co., Ltd., Aichi, Japan.
Kunoh
Y
Y
Sugiura
T
T
Nagasaka
M
M
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002026:Buformin / Q000494:pharmacology; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007773:Lactates / Q000097:blood; D051379:Mice; D008820:Mice, Obese; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014044:Tolbutamide / Q000494:pharmacology
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007773:Lactates; D010879:Piperazines; D011743:Pyrimidines; C072479:MTP 3631; D014044:Tolbutamide; D002026:Buformin